WisdoMont Asset Management
VC Fund
Huangpu, China
WisdoMont Asset Management is a Shengshan Assets is an excellent venture capital and private equity fund management company in China. Shengshan Assets closely monitors investment opportunities in medical health and smart big data under the trend of consumption upgrading.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries WisdoMont Asset Management invests in
Stages WisdoMont Asset Management invests in
Countries WisdoMont Asset Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Health Care 10 (45%)
- Medical 5 (23%)
- Pharmaceutical 4 (18%)
- Manufacturing 3 (14%)
- Big Data 2 (9%)
Stage
- Angel 8 (36%)
- Series A 7 (32%)
- Series B 4 (18%)
- Seed 1 (5%)
- Series C 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Cheng Hao
Partner
|
Partner | Total investments: 9 | Find email | |
Ganshi Xiong
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Shen Qiang
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
X-Imaging
|
X-Imaging provides full-process automation and intelligent, comprehensive solutions. They are molecules to cells for biochemistry, medical medicine, and safety inspection and testing. The product range covers food safety, drug safety, life science fields, and intelligent robot workstation systems. | $13.9M / Series B / Dec 11, 2023 | |
Hanhong Technology
|
Hanhong Technology is a biomedicine firm that specializes in drug research, innovative synthetic biology, and pharmaceutical intermediates. | $13.9M / Series A / Dec 11, 2023 | |
OBiO Technology
|
OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services. | $28.5M / Series C / Jul 08, 2020 | |
Elpiscience Biopharmaceuticals
|
Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpscience’s first therapeutic product ES101 has entered into clinical trial, and the secondinnovative product ES102 is IND ready. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by top investors such as Lilly Asia Ventures, Hillhouse Capital and CDH Investment. | $100M / Series B / Dec 28, 2019 | |
Gaochun Pharmaceutical
|
Sorghum Pharmaceuticals develops small molecule targeted innovative drugs for the unmet medical needs of autoimmune diseases and tumors. In the direction of unmet medical needs in autoimmune diseases and tumors, Gaochun Pharmaceuticals is committed to creating innovative product lines with global competitive advantages by leveraging its distinctivepharmaceutical, biological and clinical capabilities. | Corporate Round / Mar 07, 2019 | |
Cryofocus Biotech
|
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy. | $2.9M / Series A / Dec 11, 2018 | |
BANGBANG ROBOT
|
BANGBANG ROBOT manufactures and sells movable assistant robot for the disabled people. | Series A / Aug 14, 2018 | |
Weihansi Shengwu
|
Weihansi Shengwu is engaged in genetic disease screening and diagnosis, abortion product detection, single gene blockade of new mutations, and a technical service platform for gene detection of genetic diseases and the prevention and control of birth defects. | $425K / Angel / Jun 12, 2018 | |
INGEEK
|
INGEEK is engaged in research and development of big data and artificial intelligence. They are involved in the intelligent operation and maintenance business in the field of data centers. They offer geek-lite, lightweight products for the government and enterprise fields. | $425K / Angel / Jun 05, 2018 | |
HeRui BioMed
|
HeRui BioMed provides diagnostic services that include serology and stool testing for early diagnosis and inflammatory bowel disease, precision drug testing of biological preparations, blood drug concentration testing of immunosuppressants, and liver injury testing. | $1.4M / Series A / May 23, 2018 | |
| See all 22 investments → | |||
Co-Investors
Allin Capital
1 deal together
CDH Investments
1 deal together
China Galaxy Investment Management
1 deal together
Guangzhou Shiyuan Electronic Technology
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does WisdoMont Asset Management invest in?
WisdoMont Asset Management invests primarily in Health Care, Medical and Pharmaceutical startups, most often at Angel and Series A stage. Most of the 22 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact WisdoMont Asset Management?
Public channels for WisdoMont Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WisdoMont Asset Management?
The team at WisdoMont Asset Management includes Cheng Hao (Partner), Ganshi Xiong (Founding Partner) and Shen Qiang (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
